Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Allison

Showing results (251-260 of 274) with videos related to

Pageof 28
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|October 30, 1998
A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptorD L Baly, R Horuk, D G Yansura, et al.
British Journal of Clinical Pharmacology|September 9, 2015
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validationKelong Han, Thomas Peyret, Angelica Quartino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugsJune M McKoy, E Allison Lyons, Eniola Obadina, et al.
Scientific Reports|January 21, 2017
Shigatoxin encoding Bacteriophage ϕ24<sub>B</sub> modulates bacterial metabolism to raise antimicrobial toleranceG S Holt, J K Lodge, A J McCarthy, et al.
Infection and Immunity|March 26, 2003
Group A Streptococcus gene expression in humans and cynomolgus macaques with acute pharyngitisKimmo Virtaneva, Morag R Graham, Stephen F Porcella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports projectLisa A Ladewski, Steven M Belknap, Jonathan R Nebeker, et al.
Human Molecular Genetics|July 29, 2020
Insights into genetic variants associated with NASH-fibrosis from metabolite profilingJake P Mann, Maik Pietzner, Laura B Wittemans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Journal of the National Cancer Institute|September 27, 2007
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristicsJames E Allison, Lori C Sakoda, Theodore R Levin, et al.
Pageof 28

Showing results (251-260 of 274) with videos related to

Sort By:
Pageof 28
Journal of Immunology (Baltimore, Md. : 1950)|October 30, 1998
A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptorD L Baly, R Horuk, D G Yansura, et al.
British Journal of Clinical Pharmacology|September 9, 2015
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validationKelong Han, Thomas Peyret, Angelica Quartino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugsJune M McKoy, E Allison Lyons, Eniola Obadina, et al.
Scientific Reports|January 21, 2017
Shigatoxin encoding Bacteriophage ϕ24<sub>B</sub> modulates bacterial metabolism to raise antimicrobial toleranceG S Holt, J K Lodge, A J McCarthy, et al.
Infection and Immunity|March 26, 2003
Group A Streptococcus gene expression in humans and cynomolgus macaques with acute pharyngitisKimmo Virtaneva, Morag R Graham, Stephen F Porcella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports projectLisa A Ladewski, Steven M Belknap, Jonathan R Nebeker, et al.
Human Molecular Genetics|July 29, 2020
Insights into genetic variants associated with NASH-fibrosis from metabolite profilingJake P Mann, Maik Pietzner, Laura B Wittemans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Journal of the National Cancer Institute|September 27, 2007
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristicsJames E Allison, Lori C Sakoda, Theodore R Levin, et al.
Pageof 28